Project Details
Description
Phase II Study of Pembrolizumab in the Immunoreactive Ovarian Cancer Subtype
| Status | Finished |
|---|---|
| Effective start/end date | 3/6/19 → 3/30/26 |
Funding
- UNIVERSITY OF CALIFORNIA, LOS ANGELES
- MERCK
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.